Welcome, Guest
Username: Password: Remember me
Adult Stem Cell News and Developments other than Cytori
  • Page:
  • 1

TOPIC: Teva & Mesoblast cleared by FDA for phase III

Teva & Mesoblast cleared by FDA for phase III 31 Oct 2013 09:02 #1012

  • d9dozrman
  • d9dozrman's Avatar Topic Author
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 151
  • Thank you received: 21
United States Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) filing made by Mesoblast's development and commercial partner Teva Pharmaceutical Industries Ltd to commence a Phase 3 trial in patients with chronic congestive heart failure using Mesoblast's proprietary Mesenchymal Precursor Cells (MPCs). The IND was cleared by the FDA within the minimum 30-day period following submission, and patient recruitment is expected to begin shortly.

The multi-center trial, which will be conducted by Teva, is planned to enrol approximately 1,700 patients and includes two interim analyses of efficacy and/or safety. The clinical protocol was designed after initial consultation with both the FDA and the European Medicines Agency.


Partner, partner, we need a deep pocketed partner. :bash:


Please Log in or Create an account to join the conversation.

Teva & Mesoblast cleared by FDA for phase III 01 Nov 2013 08:27 #1019

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3362
  • Thank you received: 1116
On allogeneic cells, Centeno posted another article in his blog-

I’ve blogged before on the problems with allogeneic stem cells. While this is the preferred Pharma business model for stem cells because it allows cells to be mass manufactured and distributed like drugs, is it a good idea? First, while it’s been hyped that donor stem cells aren’t rejected like someone else’s heart or kidney, this is only partially true. For example, a recent research study showed that stem cells from a donor did cause the host to react negatively toward the cells (the host tried to kill them off). We also know that the genes of the donor stem cells stay working in the host. Why is this a concern? You’re buying all of your genetic predispositions plus that of the donor. Did he or she have cells that code for a cancer later in life? Who knows? We certainly don’t know at this early stage of development of routine genetic screens. In addition, for cells that are mass manufactured, there is no requirement for the companies selling these cells to screen for these possible genetic diseases. A recent study further continues this same cause for concern. The researchers looked at two patients who were given someone else’s stem cells to treat transplant rejection who later died of infection. The donor’s cells were still present in many of the patient’s organs a year later. With a traditional small molecule chemical drug this is almost never a concern, meaning you don’t worry about the drug still being in your system months or years after you’ve taken the drug. This is not the case with cell drugs. In addition, unlike getting someone else’s kidney where you know the risks (mainly of getting really sick from rejection), these genetic risks are being largely swept under the rug by the Pharma industry gearing up for mass manufactured stem cells.

The upshot? Allogeneic stem cells remain a concern and it appears that every month or two another study comes out that raises more issues. While this is a convenient way to mass produce and distribute cells like drugs, it’s looking like the mounting science is questioning the wisdom of this decision.

I have read similar stuff before- the link Centeno had was the following- Loss of immune privileged status of allo cells

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.078 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.



Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites